53 results about "Insulin tolerance" patented technology

An increase in body fat is one of main causes of life-style-related diseases such as hypertension, insulin tolerance and hyperlipemia. A composition for body fat reduction is provided which inhibits body fat from decreasing or decreasing which and which is effective in the treatment and prevention of adult diseases a cause of which is body fat. Also, provided are a medicine and a food each containing the composition.

The composition for body fat reduction comprises (A) astaxanthin and (B) at least one of active ingredient, an adsorbent and a solubilizer, a composition comprises (A) Haetmatococcusalga extract containing astaxanthin and (B) at least one of active ingredient, an adsorbent and a solubilizer, and a medicine and food, each containing the composition are provided.

Provided are picolinamide and pyrimidine-4-carboxamide compounds, a method for preparing the same, a pharmaceutical composition containing the same, and a medical use using the compound as an agent for preventing, regulating, and treating diseases related to regulation of glucocorticoids by using selective inhibitory activity of the compound for an 11β-HSD1 enzyme. The picolinamide and pyrimidine-4-carboxamide compounds of the present invention are selective inhibitors of human-derived 11β-HSD1 enzymes, and are useful in an agent for preventing, regulating, and treating diseases related to glucocorticoid regulation in which human-derived 11β-HSD1 enzymes are involved, for example, metabolic syndromes such as, type 1 and type 2 diabetes, diabetes later complications, latent autoimmune diabetes adult (LADA), insulin tolerance syndromes, obesity, impaired glucose tolerance (IGT), impaired fasting glucose (IFG), damaged glucose tolerance, dyslipidemia, atherosclerosis, hypertension, etc.

The invention discloses a Lycium ruthenicum anthocyanin and a preparation method thereof. The preparation method comprises the following steps: preparing a Lycium ruthenicum anthocyanin powder; extracting the Lycium ruthenicum anthocyanin; and purifying and freeze-drying the Lycium ruthenicum anthocyanin. The Lycium ruthenicum anthocyanin prepared in the invention has good ability to remove DPPH free radicals and hydroxyl free radicals, and has influences on fat accumulation, lipid metabolism and insulin tolerance of obese mice.

The invention designs a novel lipid-lowering polypeptide P48. The novel lipid-lowering polypeptide P48 is prolonged in a half-life period, plays the role of a GLP-1 receptor agonist and also plays therole of a GLP-1 analogue to adjust the fat content of an individual. The P48 peptide can be used for inhibiting feed intake of a non-alcoholic fatty liver model mouse induced by high-fat diet, remarkably reduce the weight of an obese mouse, lower the blood fat level of the obese mouse, maintain the normal form of the liver, inhibit liver cell injury, reduce accumulation of lipid in the liver andvacuolar deformation of cells, increase the level of adiponectin leptin in blood, and give a play to the blood glucose reducing and blood fat regulating effects of the adiponectin leptin; meanwhile, the P48 peptide obviously improves insulin tolerance and sugar tolerance. The novel lipid-lowering polypeptide P48 of the invention has potential pharmaceutical application in preparation of drugs fortreating and preventing obesity or complications thereof, namely non-alcoholic fatty liver diseases.

The invention provides medical application of a genistein chromium complex to treatment of diabetes. Results of the animal growth condition research, fasting blood-glucose value determination, glucose tolerance test, insulin tolerance test show that the genistein chromium complex has an excellent hypoglycemic effect, and can be used for preparing drugs for treating diabetes II; by combing the hypoglycemic advantage of chromium, the hypoglycemic activity of genistein is improved obviously and toxicity of inorganic chromium can be reduced.

The invention discloses a method for establishing an insulin resistance animal model. According to the method, feed with high content of selenium, sugar and fat and low-concentration fructose drinkingwater are used for inducing inbred line C57BL/6 mice with highly similar genetic backgrounds in order to cause glycolipid metabolism disorder of the mice and then induce the occurrence of insulin resistance, and then the insulin resistance animal model is established. Through unique proportioning of the feed, a pathogenesis process of the insulin resistance caused by the change of a dietary structure is highly simulated, comparison between the induced animal model and a control group shows that animals in a model group are obviously different from animals in the normal control group in intakeglucose tolerance, insulin tolerance, animal insulin resistance index and insulin sensitivity index, and it is indicated that the animals in the model group have obvious insulin resistance. The method has the advantages that the special feed is adopted for feeding in two modes, adverse reactions caused by chemical reagents are eliminated, a molding method is simple, the molding rate is high, thecost is low, and the reproducibility is high.

The invention discloses a resistin polypeptide vaccine and application thereof to the treatment of a mammary cancer, and belongs to the technical field of biology. A polypeptide vaccine provided by the invention is prepared from a Resistin-protein specific polypeptide segment and an immunologic adjuvant, and becomes the Resistin polypeptide vaccine. Through multiple subcutaneous injections, the vaccine can be used for activating the lymphocyte of an organism, and generates an immune neutralizing antibody aiming at Resistin protein. The Resistin polypeptide vaccine does not influence the sugartolerance and insulin tolerance levels of the organism at all. The Resistin polypeptide vaccine can be used for obviously inhibiting the growth of an ER (Estrogen Receptor) positive mammary tumor anda triple-negative mammary tumor under a mouse model; in addition, the Resistin polypeptide vaccine can be used for obviously inhabiting the growth of the ER positive mammary tumor and the triple-negative mammary tumor of a mouse under an obesity model induced by a high fat diet, and a new way is provided for ameliorating a current treatment method of the mammary cancer by the resistin polypeptidevaccine.

The invention provides a COX18 polypeptide with biological activity. An amino acid sequence of the polypeptide is as shown in SEQ ID NO. 1: LLPAGWILSH LETYRRPE. The invention further provides a methodfor synthesizing the COX18 polypeptide through a chemical synthesis method, namely an Fmoc method as well as application, and the polypeptide is applicationd for preparing drugs which inhibit sugar induced insulin secretion, resist insulin tolerance, resist hyperinsulinemia and reduce body weight. The invention finds a novel COX18 polypeptide which is 52-69th part of human cytochrome c oxidase 8A, which is different from the precious porcine sequence. Compared with the previous sequence, the sequence has 38.88% of different amino acid. Moreover, the sequence is humanized, and has better homology, fewer immunoreactions and side effects while being applied to a human body.

The invention provides monoclonal antibody 3H6 and related antibodies. The 3H6 antibody binds to an epitope within residues 28-36 of IAPP. The antibodies of the invention are useful, for example, for treating disorders associated with IAPP accumulation, particularly accumulation of IAPP deposits. Such disorders include type 2 diabetes, metabolic syndrome, impaired insulin tolerance, impaired glucose tolerance, insulinomas, and related conditions.

The invention provides monoclonal antibody 6B8 and related antibodies. The 6B8 antibody binds to an epitope within residues 3-12 of IAPP. The antibodies of the invention are useful, for example, for treating disorders associated with IAPP accumulation, particularly accumulation of IAPP deposits. Such disorders include type 2 diabetes, metabolic syndrome, impaired insulin tolerance, impaired glucose tolerance, insulinomas, and related conditions.

The invention discloses a method for building a small intestine insulin expression reduction rat model by an adenovirus vector. The method mainly comprises the steps of adenovirus vector building andrat small intestine transfection by the adenovirus vector. The characteristic that the adenovirus vector carries rat antisense mRNA insulin gene is utilized; through rat gavage, the rat small intestine insulin expression reduction can be built within three months; the reduction of rat insulin tolerance and oral glucose tolerance can be caused. The animal model has wide application prospects for further developing medicine for treating diabetes.

The invention relates to application of a cationic polymer in preparation of a medicine for preventing or treating diseases caused by toxins generated by intestinal microorganisms or diseases caused by new coronavirus infection. Toxin released by intestinal microorganisms can be neutralized and cleared by oral administration of cationic polymers, and most of these microbial toxins present anionic acidity. By adopting the application, various intestinal microbial toxins entering blood can be reduced; therefore, systemic inflammation, local inflammation, hepatic failure and liver injury, insulin tolerance, fatty liver disease, lung failure, kidney failure, hepatic encephalopathy, septicemia and inflammatory storm, severe illness and the like caused by novel coronavirus infection are relieved; the traditional Chinese medicine composition can also be used for treating ICU patients, reducing systemic inflammation, recovering organ functions and improving the survival rate, and can also be used for preventing or treating chronic inflammation and various metabolic diseases caused by intestinal bacterial toxins, preventing and treating fatty liver diseases, relieving insulin tolerance, relieving diabetes mellitus and relieving obesity.

The invention relates to a cyclic peptide capable of reducing insulin, not increasing blood sugar but properly reducing blood sugar at the same time, and belongs to the technical field of biological pharmacy. The bifunctional cyclic peptide is obtained through in-vitro modification on the basis of an original linear short peptide COX52-69; the effects of two seemingly contradictory aspects are achieved; namely, the effect of inhibiting insulin secretion but not increasing blood sugar at the same time is achieved; blood sugar is reduced; and the mechanism of the bifunctional cyclic peptide is possibly to improve the sensitivity of tissue to insulin. It is called as a bifunctional peptide. The bifunctional peptide can be used for congenital insulinemia, insulin tolerance, hyperinsulinemia of obese people and the like; literatures report that insulin increase is the reason of obesity; but people cannot lose weight through a method of reducing insulin all the time; and because blood sugar is increased after insulin is reduced, hyperglycemia is more adverse to health. The cyclic peptide realizes the function that the blood sugar is not increased but is reduced while insulin is reduced, so that a new medicine is developed for treating obesity; and the medicine not only can be administrated by injection, but also can be conveniently administrated by oral administration. The convenience of using the medicine is greatly improved.

Disclosed herein are apparatuses and methods that account for meal announcements in closed loop insulin delivery systems. Rather than simply increasing an insulin delivery rate in response to the meal announcement, the closed loop algorithm can be modified to increase the insulin on board tolerance during eating periods. This approach utilizes the stability of the cascaded loop in the closed loop algorithm to prevent the oscillations in glucose levels that can occur by simply increasing the basal rate.

The present invention relates to a method of determining a blood lipid profile associated with insulin tolerance. The method comprising the steps: determining insulin tolerance of a series of biological systems; determining one or more blood lipid profiles of a series of biological system samples; utilizing multivariable analysis to determine the correlation between insulin tolerance and one or more blood lipid profiles; and selecting the correlation between insulin tolerance and one or more blood lipids. According to the method, the correlation between one or more blood lipid profiles of thebiological system and the insulin tolerance of the biological system is determined through the multivariable analysis method, the insulin tolerance of the biological system can be determined accordingto the detection condition of blood lipid in practical application according to the correlation and the method is simple and low in cost.